Discrimination by SZL49 between contractions evoked by noradrenaline in longitudinal and circular muscle of human vas deferens

[1]  J. Docherty,et al.  Investigation of the subtypes of α1‐adrenoceptor mediating contractions of rat vas deferens , 1999 .

[2]  P. H. van der Graaf,et al.  Analysis of α1L‐adrenoceptor pharmacology in rat small mesenteric artery , 1999 .

[3]  J. Gever,et al.  Human cloned α1A-adrenoceptor isoforms display α1L-adrenoceptor pharmacology in functional studies , 1999 .

[4]  J. Guillebaud,et al.  Functional characterization of alpha1-adrenoceptor subtypes in longitudinal and circular muscle of human vas deferens. , 1999, European journal of pharmacology.

[5]  Y. Watanabe,et al.  Binding and functional characterization of alpha1-adrenoceptor subtypes in the rat prostate. , 1999, European journal of pharmacology.

[6]  N. Flavahan,et al.  α1l-adrenoceptors in Canine Pulmonary Artery , 1998 .

[7]  A. Ford,et al.  α1L‐Adrenoceptor mediation of smooth muscle contraction in rabbit bladder neck: a model for lower urinary tract tissues of man , 1998, British journal of pharmacology.

[8]  C. Chapple,et al.  α1A‐Adrenoceptor mediated contraction of rat prostatic vas deferens and the involvement of ryanodine stores and Ca2+ influx stimulated by diacylglycerol and PKC , 1998, British journal of pharmacology.

[9]  H. Nishimatsu,et al.  Quantification and distribution of α1‐adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions , 1997, British Journal of Pharmacology.

[10]  J. Gever,et al.  Pharmacological pleiotropism of the human recombinant α1A‐adrenoceptor: implications for α1‐adrenoceptor classification , 1997 .

[11]  J. Hieble,et al.  Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part II. , 1997, The Journal of pharmacology and experimental therapeutics.

[12]  A. Ford,et al.  Pharmacological characterization of an α1A‐adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat , 1997, British journal of pharmacology.

[13]  J. Hieble,et al.  Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I. , 1997, The Journal of pharmacology and experimental therapeutics.

[14]  A. Noble,et al.  The effects of SB 216469, an antagonist which discriminates between the α1A‐adrenoceptor and the human prostatic α1‐adrenoceptor , 1996 .

[15]  C. Chapple,et al.  Different subtypes of α1A‐adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053 , 1996, British journal of pharmacology.

[16]  A. Naylor,et al.  Evaluation of the pharmacological selectivity profile of α1 adrenoceptor antagonists at prostatic α1 adrenoceptors: binding, functional and in vivo studies , 1996 .

[17]  S. Meretyk,et al.  Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. , 1996, The Journal of pharmacology and experimental therapeutics.

[18]  T. Stamey,et al.  RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. , 1996, Molecular pharmacology.

[19]  R. Chess-Williams,et al.  α1A‐Adrenoceptor‐mediated contractile responses of the human vas deferens , 1995, British journal of pharmacology.

[20]  I. Muramatsu,et al.  Identification of alpha 1-adrenoceptor subtypes in the rabbit prostate. , 1995, Journal of autonomic pharmacology.

[21]  I. Marshall,et al.  Noradrenaline contractions of human prostate mediated by α1c‐(α1c‐) adrenoceptor subtype , 1995 .

[22]  C. Chapple,et al.  Evidence for a functional α1A‐ (α1C‐) adrenoceptor mediating contraction of the rat epididymal vas deferens and an α1B‐adrenoceptor mediating contraction of the rat spleen , 1995 .

[23]  R. Lefkowitz,et al.  International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. , 1995, Pharmacological reviews.

[24]  A. Ford,et al.  Functional evidence equating the pharmacologically‐defined α1A‐ and cloned α1C‐adrenoceptor: studies in the isolated perfused kidney of rat , 1995 .

[25]  N. Amobi,et al.  The human vas deferens: correlation of response pattern to noradrenaline and histological structure. , 1995, European journal of pharmacology.

[26]  C. Chapple,et al.  Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype. , 1995, British journal of pharmacology.

[27]  H. Akino,et al.  Pharmacological characterization of alpha 1-adrenoceptor subtypes in the human prostate: functional and binding studies. , 1994, British journal of urology.

[28]  J. Hieble,et al.  New directions in adrenoceptor pharmacology. , 1994, Trends in pharmacological sciences.

[29]  I. Muramatsu,et al.  Heterogeneity of α1‐adrenoceptor subtypes involved in adrenergic contractions of dog blood vessels , 1994, British journal of pharmacology.

[30]  A. Ford,et al.  α1-Adrenoceptor classification: sharpening Occam's razor , 1994 .

[31]  J. Docherty,et al.  Investigation of the subtypes of α1‐adrenoceptor mediating contractions of rat aorta, vas deferens and spleen , 1993, British journal of pharmacology.

[32]  I. Muramatsu,et al.  Pharmacological characterization of two distinct α1‐adrenoceptor subtypes in rabbit thoracic aorta , 1993, British journal of pharmacology.

[33]  I. Muramatsu,et al.  Identification of α1‐adrenoceptor subtypes in the rat vas deferens: binding and functional studies , 1992 .

[34]  J. Sallés,et al.  Mechanisms underlying the differential sensitivity to a1‐adrenoceptor activation in the bisected rat vas deferens , 1991, British journal of pharmacology.

[35]  I. Muramatsu,et al.  Subtypes of alpha 1-adrenoceptors involved in noradrenaline-induced contractions of rat thoracic aorta and dog carotid artery. , 1991, Japanese journal of pharmacology.

[36]  M. Piascik,et al.  Agonist interaction with alkylation-sensitive and -resistant alpha-1 adrenoceptor subtypes. , 1990, The Journal of pharmacology and experimental therapeutics.

[37]  I. Muramatsu,et al.  Pharmacological subclassification of α1‐adrenoceptors in vascular smooth muscle , 1990 .

[38]  I. Smith,et al.  Direct and indirect contractile responses of the human vas deferens and actions of noradrenaline and of calcium antagonists , 1990, Experimental physiology.

[39]  M. Martí,et al.  Relationship between α-adrenoceptor occupancy and contractile response in rat vas deferens. Experimental and theoretical analysis☆ , 1988 .

[40]  J. McGrath,et al.  Alpha-adrenoceptor subclassification by classical and response-related methods: same question, different answers. , 1988, Trends in pharmacological sciences.

[41]  N. Flavahan,et al.  α1-Adrenoceptor subclassification in vascular smooth muscle , 1986 .

[42]  K. Andersson,et al.  Effect of drugs interacting with adrenoreceptors and muscarinic receptors in the epididymal and prostatic parts of the human isolated vas deferens. , 1985, Journal of autonomic pharmacology.

[43]  P. Abel,et al.  "Spare" alpha 1-adrenergic receptors and the potency of agonists in rat vas deferens. , 1984, Molecular pharmacology.

[44]  P. Abel,et al.  Occupancy of alpha 1-adrenergic receptors and contraction of rat vas deferens. , 1983, Molecular pharmacology.

[45]  R. Ruffolo.  IMPORTANT CONCEPTS OF RECEPTOR THEORY , 1982 .

[46]  R. Furchgott,et al.  COMPARISON OF DISSOCIATION CONSTANTS AND OF RELATIVE EFFICACIES OF SELECTED AGONISTS ACTING ON PARASYMPATHETIC RECEPTORS * , 1967 .